Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

2105 - Prognostic Associations of Prostate-Specific Antigen (PSA) Decline With Survival, Radiographic Response and Progression in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide

Date

10 Sep 2017

Session

Genitourinary tumours, prostate

Presenters

Andrew Armstrong

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

A.J. Armstrong1, P. Lin2, C.S. Higano3, P. Iversen4, C.N. Sternberg5, B. Tombal6, D. Phung7, T. Parli8, A. Krivoshik9, T.M. Beer10

Author affiliations

  • 1 Divisions Of Medical Oncology And Urology, Duke Cancer Institute, 27710 - Durham/US
  • 2 Biometrics, Medivation, Inc. (Medivation was acquired by Pfizer, Inc. in Sept 2016), 94105 - San Francisco/US
  • 3 Medicine And Urology, University of Washington Seattle Cancer Care Alliance, 98109 - Seattle/US
  • 4 Urology, Rigshospitalet, University of Copenhagen, 2100 - Copenhagen/DK
  • 5 Department Of Oncology, San Camillo and Forlanini Hospitals, 156 - Roma/IT
  • 6 Urology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 7 Biostatistics, Astellas Pharma Europe B.V., 2333 BE - Leiden/NL
  • 8 Clinical Development, Medivation, Inc. (Medivation was acquired by Pfizer, Inc. in Sept 2016), 94105 - San Francisco/US
  • 9 Medical Sciences - Oncology, Astella Pharma, Inc., 60062 - Northbrook/US
  • 10 Oregon Health & Science University, OHSU Knight Cancer Institute, 97239 - Portland/US
More

Resources

Abstract 2105

Background

In the PREVAIL clinical trial, enzalutamide provided significant improvements vs placebo in radiographic progression-free survival (rPFS) and overall survival (OS) in chemotherapy-naïve men with mCRPC. This post hoc analysis aimed to evaluate the prognostic association between the magnitude of PSA decline from baseline and clinical outcomes in PREVAIL.

Methods

Men from the enzalutamide and placebo arms of PREVAIL were grouped into categories of confirmed maximal PSA decline from baseline at month 3 of treatment: no decline/decline < 30% and ≥ 30%, ≥ 50% or ≥ 90% decline. Confirmation required PSA decline on ≥ 1 consecutive visit after month 3. Best overall soft-tissue response (per RECIST v1.1) was determined for patients with measurable disease at baseline (data cutoff: 16 Sep 2013). Time to PSA progression (data cutoff: 16 Sep 2013), rPFS (per PCWG2; data cutoff: 6 May 2012) and OS (data cutoff: 16 Sep 2013) were estimated using the Kaplan-Meier method.

Results

In PREVAIL, men were randomized to enzalutamide (n = 872) or placebo (n = 845). Most men in the placebo arm (66%, 558/845) had no PSA decline/decline < 30%, in contrast to 11% (94/872) in the enzalutamide arm. In the enzalutamide arm, 81% (701/872) of men had a PSA decline of ≥ 30% from baseline at week 13, 73% (639/872) had a PSA decline of ≥ 50% and 35% (307/872) had a PSA decline of ≥ 90%. Key outcomes for the enzalutamide arm are provided by PSA decline category in the Table. PSA flare (rise followed by a fall) after 3 months was rare with enzalutamide (< 1%).Table:

787PD

OutcomeMaximal PSA Decline From Baseline at Month 3 in the Enzalutamide Arm (N = 872)
No Decline/ Decline < 30%≥ 30% Decline≥ 50% Decline≥ 90% Decline
(n = 94/872)(n = 701/872)(n = 639/872)(n = 307/872)
Best objective soft-tissue response (CR or PR), % (95% CI)12.0 (4.5-24.3)70.6 (65.1-75.6)74.8 (69.2-79.9)89.7 (82.8-95.0)
Median (95% CI) time to PSA progression, mo3.7 (3.7-4.6)13.8 (11.3-14.0)13.9 (13.8-16.6)22.5 (16.8-NYR)
Median (95% CI) rPFS, mo7.9 (3.7-NYR)NYR (13.8-NYR)NYR (13.8-NYR)NYR (13.8-NYR)
HR (95% CI) for rPFS1.0 (ref)0.20 (0.13-0.31)0.17 (0.11-0.27)0.10 (0.05-0.19)
Median (95% CI) OS, mo23.1 (17.8-28.0)32.4 (31.5-NYR)NYR (31.5-NYR)NYR (NYR-NYR)
HR (95% CI) for OS1.0 (ref)0.31 (0.22-0.42)0.28 (0.20-0.39)0.19 (0.12-0.28)

Abbreviations: CI, confidence interval; CR, complete response; HR, hazard ratio; mo, months; NYR, not yet reached; OS, overall survival; PR, partial response; PSA, prostate-specific antigen; ref, reference, rPFS, radiographic progression-free survival.

Conclusions

PSA declines after 3 months of enzalutamide therapy are strongly associated with soft-tissue response and improvements in rPFS and OS. Providing updated prognostic information to chemotherapy-naïve men with mCRPC can be of clinical value given the heterogeneity of long-term outcomes.

Clinical trial identification

NCT01212991

Legal entity responsible for the study

This study was sponsored by Medivation, Inc. (which was was acquired by Pfizer, Inc. in September 2016) and Astellas Pharma, Inc., the co-developers of enzalutamide.

Funding

This study was sponsored by Medivation, Inc., (which was acquired by Pfizer, Inc. in September 2016) and Astellas Pharma, Inc., the co-developers of enzalutamide.

Disclosure

A.J. Armstrong: Consultant: Bayer, Sanofi, Novartis, Dendreon, Medivation, Janssen Biotech, Eisai Bureau: Dendreon, Sanofi, Medivation, Janssen Biotech Grant/Patent (inst) Dendron, Sanofi, Bayer, Pfizer, Novartis, BMS, Janssen Oncology, Medivation, Astellas, Gilead. P. Lin, T. Parli: Employment: Pfizer, Inc. C.S. Higano: Consulting/Travel: Dendreon, Bayer, Medivation, Ferring, J&J, AbbVie, Genentech, Pfizer, BHR, Orion, Sanofi, Amgen, Ockham, Teva, Astellas. P. Iversen: Consultant/Advisor, Meeting Participant/Lecturer, Scientific Study/Trial and Clinical Research Collaboration: Astellas Pharma, Medivation. C.N. Sternberg: Honoraria: Pfizer, Bristol-Myers Squibb, Novartis, Janssen, Bayer, Astellas Pharma, Sanofi, Eisai, Ipsen, GlaxoSmithKline, MSD. B. Tombal: Consulting: Astella, Bayer, Ferring, Janssen, Takeda, Steba Biotech, Sanofi Speakers Bureau: Amgen, Janssen Travel/Honoraria: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi. D. Phung: Employment: Astellas Pharma. A. Krivoshik: Employment and Travel/Expenses: Astellas Pharma Stock/Ownership Interests: Abbott Laboratories, AbbVie. T.M. Beer: Consulting: Astellas, Bayer, Dendreon, Janssen Japan, Novartis, AstraZeneca, Churchill, Proacta Stock/Ownership: Salarius.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.